1h Free Analyst Time
ThesiRNA Therapeutics Market was valued at USD 2.95 billion in 2024 and is projected to grow to USD 3.25 billion in 2025, with a CAGR of 10.35%, reaching USD 5.33 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Pioneering the Future of siRNA Therapeutics
In recent years, small interfering RNA therapies have emerged as a transformative class of gene silencing modalities with the potential to address previously intractable diseases. By leveraging the natural mechanism of RNA interference, these therapies offer unprecedented specificity and durability, marking a paradigm shift in precision medicine. This executive summary outlines the key trends, challenges, and strategic imperatives that define the current siRNA therapeutics landscape, providing decision-makers with a cohesive overview of market drivers and critical inflection points.The market has witnessed accelerating clinical approvals alongside innovative delivery platforms that overcome longstanding barriers to cellular uptake and endosomal escape. Concurrently, evolving regulatory frameworks and emerging tariff regimes introduce new complexities, compelling stakeholders to refine supply chain strategies and foster dynamic collaborations. Grounded in comprehensive primary interviews with industry leaders and rigorous secondary research, this analysis distills actionable insights that will empower pharmaceutical developers, investors, and research institutions to navigate the rapidly evolving siRNA ecosystem with confidence.
Structured around five core segmentation dimensions, this report examines drug agents spanning clinically approved constructs, delivery systems ranging from lipid nanoparticles to polymer conjugates, routes of administration including intravenous and subcutaneous applications, therapeutic categories covering cardiovascular, immunological, infectious, metabolic, neurological, and oncological indications, and end-user profiles encompassing contract research organizations, healthcare providers, pharmaceutical firms, and academic institutions. A detailed regional analysis dissects market dynamics across the Americas, Europe, Middle East and Africa, and Asia-Pacific, while strategic recommendations and a transparent methodology ensure the credibility and practical relevance of the findings.
Revolutionary Advances Shaping the siRNA Landscape
Innovation in delivery technologies has catalyzed a new era for siRNA-based treatments, overcoming historical obstacles related to stability and cellular uptake. Advances in lipid nanoparticle formulations have significantly enhanced endosomal escape and biodistribution, while emerging peptide delivery systems offer alternative chassis for targeted tissue penetration. Polymer conjugates are likewise gaining prominence by providing tunable pharmacokinetics and reduced immunogenic profiles. These technological breakthroughs have accelerated the transition from preclinical promise to clinical validation, setting the stage for broader therapeutic applications.In parallel, regulatory bodies are increasingly receptive to siRNA modalities, as evidenced by streamlined approval pathways and adaptive licensing frameworks. Recent guidance documents have clarified potency assays and safety benchmarks, enabling developers to engage in earlier dialogue with regulatory agencies and to implement more efficient trial designs. This regulatory alignment has bolstered investor confidence and reduced time to market for next-generation candidates.
Strategic alliances between biotech startups, academic research centers, and established pharmaceutical corporations are reshaping the competitive landscape. Collaborative consortia and licensing agreements are facilitating the sharing of proprietary delivery platforms, proprietary sequences, and manufacturing capabilities. At the same time, cross-sector partnerships with contract research organizations and contract manufacturing organizations are optimizing development timelines and de-risking scale-up processes. Collectively, these transformative forces are redefining the siRNA field, creating an environment ripe for sustained innovation and commercial expansion.
Scale-up manufacturing processes have also undergone refinement, with continuous flow synthesis and novel purification techniques enhancing throughput and yield. Analytical methods for characterizing modified oligonucleotides are evolving to support robust quality control, and end-to-end supply chain digitalization is improving transparency and traceability. These operational innovations are critical for sustaining late-stage pipeline progression and for achieving commercial scale at competitive cost points.
Evaluating the Impact of 2025 US Tariffs on siRNA Supply Chains
Recent shifts in U.S. trade policy, culminating in the imposition of targeted tariffs on key raw materials and delivery substrates, are set to reverberate across the siRNA supply chain. Components such as specialized lipids, synthetic oligonucleotides, and enzymatic reagents now face incremental cost pressures, challenging developers to reassess procurement strategies and renegotiate supplier contracts. These tariffs also introduce uncertainty in project budgeting, potentially delaying milestone payments and clinical enrollment timelines.Producers of lipid nanoparticles, peptide conjugates, and polymer backbones may encounter margin compression as tariffs filter through manufacturing cost structures. Companies reliant on offshore synthesis of modified nucleotides or advanced formulation excipients must weigh the benefits of nearshoring supply against potential quality and scalability trade-offs. Early engagement with alternative suppliers and vertical integration of critical production steps can mitigate exposure to tariff volatility, though such strategic pivots may require additional capital investment and operational realignment.
In response, stakeholder groups are exploring collaborative purchasing consortia and leveraging customs bonding arrangements to defer duty payments. Pharmaceutical sponsors are also accelerating validation of domestic manufacturing sites and pursuing regulatory approvals for localized production. This environment may compel sponsors to explore hedging strategies and dynamic cost modeling to preserve budget margins across multi-year clinical programs. By proactively adjusting their supply chain architectures and strengthening supplier relationships, organizations can preserve development timelines and control overall program costs despite the evolving tariff environment. The net effect will be a more resilient and flexible supply network capable of supporting the sustained growth of the siRNA therapeutic pipeline.
Unraveling Market Segmentation to Illuminate Growth Drivers
Demystifying the intricate fabric of the siRNA landscape requires a holistic view across multiple segmentation dimensions. The drug agent segment encompasses a diverse roster of molecules, with Givosiran, Inclisiran, Lumasiran, Nedosiran, Patisiran and Vutrisiran each offering unique mechanisms of action and clinical positioning. Parallel to this, the delivery systems dimension spotlights the critical role of lipid nanoparticles, peptide delivery systems and polymer conjugates in modulating pharmacokinetics and targeting efficiency.Routes of administration exert a profound influence on patient acceptability and therapeutic index, with intravenous formulations delivering rapid systemic exposure and subcutaneous injections facilitating outpatient convenience. The therapeutic categories dimension spans cardiovascular disorders, immunological disorders, infectious diseases dissected into bacterial infections and viral infections, metabolic disorders, neurological disorders further divided into Alzheimer’s disease and Parkinson’s disease, and oncology further segmented into hematologic malignancies such as leukemia and lymphoma as well as solid tumors including breast, lung and prostate cancers.
Finally, the end-user dimension captures the ecosystem of Contract Research Organizations, Hospitals and Clinics, Pharmaceutical Companies and Research and Academic Institutes that drive demand and service delivery. By integrating these segmentation lenses, stakeholders can pinpoint high-growth submarkets, align portfolio strategies with unmet clinical needs and allocate resources to areas with maximal return on investment. This granular understanding of segment-specific dynamics forms the basis for targeted R&D initiatives and informed commercial planning, ensuring that emerging siRNA assets achieve both therapeutic impact and financial viability.
Uncovering Regional Dynamics Across the Global siRNA Market
Understanding regional nuances is essential for charting strategic market entry and expansion. In the Americas, robust venture capital investment, accelerated adoption of advanced therapies, and a mature regulatory environment position the United States as a leading innovation hub. Canada’s growing biomanufacturing infrastructure and supportive reimbursement policies further complement the region’s appeal. Across Latin America, selective government incentives are beginning to catalyze early-stage research collaborations, signaling untapped potential.Europe, the Middle East and Africa exhibit a mosaic of regulatory and reimbursement landscapes. The European Union’s centralized approval process and emerging Health Technology Assessment frameworks establish a solid foundation for siRNA adoption, particularly in countries such as Germany, France and the Nordics. Simultaneously, the Gulf region is investing heavily in biotech clusters and clinical trial infrastructure, while sub-Saharan markets remain nascent but characterized by a high burden of genetic disorders that could benefit from targeted RNA therapies.
In the Asia-Pacific region, governmental initiatives in China, Japan and South Korea are driving large-scale biopharmaceutical R&D programs and incentivizing domestic production of oligonucleotide therapeutics. Collaborative partnerships between multinational and local players accelerate technology transfer and clinical development. Emerging markets in Southeast Asia and Oceania are gradually aligning regulatory standards and expanding reimbursement schemes, creating new avenues for siRNA deployment. These regional dynamics underscore the importance of tailored market strategies that align with local regulatory, clinical and economic contexts.
Profiling Leading Innovators Advancing siRNA Therapies
Leading the charge in siRNA innovation, Alnylam Pharmaceuticals continues to set industry benchmarks with a diverse pipeline and proven delivery platforms. Its strategic alliances and focus on rare genetic disorders have established a roadmap for translating RNA interference into commercial success. Silence Therapeutics complements this by prioritizing targeted respiratory and oncology applications, leveraging proprietary lipid nanoparticle technologies to enhance tissue specificity.Dicerna Pharmaceuticals distinguishes itself through collaborative partnerships with larger biopharmaceutical firms, accelerating the co-development of pipeline candidates and expanding its footprint in hepatic and central nervous system indications. Early-stage pioneers such as Arrowhead Pharmaceuticals focus on next-generation conjugation chemistries, aiming to refine endosomal release and achieve differentiated clinical profiles. Meanwhile, modular platform providers like Ionis Pharmaceuticals bridge the gap between discovery and development, offering customizable synthesis and scalable manufacturing of chemically modified oligonucleotides.
Contract research and manufacturing specialists such as Catalent and Lonza play a pivotal role in enabling rapid translation from concept to clinic, providing tailored services that address formulation, analytical validation and regulatory support. Emerging biotech entities in Asia, including Prime Medicine and Suzhou Ribo Life Science, are carving out space through government-sponsored research initiatives and localized manufacturing capabilities. In addition to these mainstays, emerging players with niche platforms are driving next-generation research, underscoring the importance of agile investment approaches. Together, these companies form a dynamic ecosystem in which innovation, strategic partnerships and operational excellence converge to drive the next wave of siRNA therapeutic breakthroughs.
Strategic Recommendations to Seize Emerging Opportunities
To capitalize on the accelerating momentum in siRNA therapeutics, industry leaders must adopt an integrated strategy that aligns scientific innovation with operational agility. First, prioritizing investment in versatile delivery platforms such as advanced lipid nanoparticle formulations and peptide conjugates will unlock new target tissues and expand therapeutic indices. Concurrently, establishing redundant supply chain partnerships and exploring regional manufacturing hubs will mitigate geopolitical and tariff-related risks while ensuring continuity of critical raw material sourcing.Second, fostering cross-disciplinary collaborations between academic research institutions, clinical centers and commercial entities can expedite translational pipelines. Co-development models and open innovation frameworks should be leveraged to share proprietary technologies, co-fund pivotal trials and accelerate regulatory submissions. This collaborative ethos will not only reduce development timelines but also diversify clinical portfolios to address emerging patient needs.
Third, proactive engagement with regulatory stakeholders across key geographies is essential to shape adaptive pathways for novel siRNA constructs. By participating in early scientific advice meetings and contributing to policy consultations, developers can influence standards for potency assays, safety evaluations and post-marketing surveillance, thereby smoothing approval trajectories.
Finally, a focused approach to therapeutic area selection-targeting high unmet need segments such as rare metabolic disorders, central nervous system conditions and select oncology indications-will maximize return on R&D investment. Aligning commercialization strategies with payer evidence requirements and real-world data generation will further ensure that promising siRNA therapies achieve rapid market access and sustainable reimbursement.
Rigorous Methodology Underpinning Market Insights
In conducting this analysis, a multi-tiered research methodology was employed to ensure rigor and reliability. Primary research involved in-depth interviews with senior executives, clinical investigators and thought leaders across biotechnology firms, pharmaceutical corporations, contract research organizations and regulatory bodies. These qualitative insights were triangulated with quantitative data drawn from proprietary databases, financial reports, clinical trial registries and peer-reviewed publications.A systematic review of secondary sources provided historical context and validated trend trajectories, while data from international trade and customs records informed the assessment of tariff impacts. The segmentation framework was developed through an iterative process of market mapping and expert validation, ensuring comprehensive coverage of drug agents, delivery technologies, administration routes, therapeutic categories and end-user segments.
Regional market sizing and dynamics were analyzed by synthesizing country-specific regulatory filings, reimbursement dossiers and government incentive programs. Key company profiles were constructed using a combination of published corporate disclosures, patent landscape analyses and technology scouting reports. Finally, all findings were subjected to an internal peer review process to verify accuracy, eliminate bias and ensure the actionable relevance of the recommendations presented herein.
Conclusive Reflections on siRNA Therapeutic Evolution
As siRNA therapeutics advance from experimental constructs to clinically validated products, the industry stands at a watershed moment defined by technological breakthroughs, regulatory convergence and strategic collaborations. The emergence of robust delivery systems has unlocked the potential of RNA interference, while adaptive regulatory frameworks and thoughtful tariff mitigation strategies are shaping a resilient global supply chain. Together, these forces are enabling developers to pursue novel indications spanning rare genetic diseases, cardiovascular conditions, infectious disorders and oncology.Detailed market segmentation reveals nuanced opportunities across diverse patient populations, with specific drug agents, delivery modalities and therapeutic categories exhibiting differentiated growth trajectories. Regional analyses highlight the Americas as a capital-rich, innovation-driven market, EMEA as a regulatory harmonization hub with expanding clinical capacity, and Asia-Pacific as a fast-growing epicenter of manufacturing and R&D investment.
By implementing the strategic recommendations outlined-focusing on delivery platform diversification, collaborative development models, regulatory engagement and targeted therapeutic area selection-stakeholders can navigate emerging challenges and capitalize on high-impact opportunities. Looking forward, the convergence of artificial intelligence with high-throughput screening is set to accelerate target discovery and sequence optimization, while advances in scalable manufacturing will reduce production costs and broaden patient access. Stakeholders that integrate these emerging technologies into their development frameworks will gain a sustainable competitive edge and be well positioned to deliver next-generation siRNA therapies to global markets.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:- Drug Agent
- Givosiran
- Inclisiran
- Lumasiran
- Nedosiran
- Patisiran
- Vutrisiran
- Delivery Systems
- Lipid Nanoparticles
- Peptide Delivery Systems
- Polymer Conjugates
- Route of Administration
- Intravenous (IV)
- Subcutaneous
- Therapeutic Categories
- Cardiovascular Disorders
- Immunological Disorders
- Infectious Diseases
- Bacterial Infections
- Viral Infections
- Metabolic Disorders
- Neurological Disorders
- Alzheimer's Disease
- Parkinson's Disease
- Oncology
- Hematologic Malignancies
- Leukemia
- Lymphoma
- Solid Tumors
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Hematologic Malignancies
- End-User
- Contract Research Organizations
- Hospitals & Clinics
- Pharmaceutical Companies
- Research & Academic Institutes
- Americas
- United States
- California
- Texas
- New York
- Florida
- Illinois
- Pennsylvania
- Ohio
- Canada
- Mexico
- Brazil
- Argentina
- United States
- Europe, Middle East & Africa
- United Kingdom
- Germany
- France
- Russia
- Italy
- Spain
- United Arab Emirates
- Saudi Arabia
- South Africa
- Denmark
- Netherlands
- Qatar
- Finland
- Sweden
- Nigeria
- Egypt
- Turkey
- Israel
- Norway
- Poland
- Switzerland
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Indonesia
- Thailand
- Philippines
- Malaysia
- Singapore
- Vietnam
- Taiwan
- Alnylam Pharmaceuticals Inc.
- Alys Pharmaceuticals Inc.
- Arbutus Biopharma Corporation
- Arcturus Therapeutics, Inc. by Alcobra Ltd.
- Aro Biotherapeutics Co.
- Arrowhead Pharmaceuticals Inc.
- Atalanta Therapeutics
- Biocon Ltd.
- e-Therapeutics Plc
- Eli Lilly and Company
- Ionis Pharmaceuticals Inc.
- Merck & Co. Inc.
- Moderna Therapeutics
- Novartis AG
- Novo Nordisk A/S
- Phio Pharmaceuticals, Inc.
- Quark Pharmaceuticals inc.
- Risen Pharma Tech Co Ltd
- Roche Holding AG
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Silence Therapeutics plc
- Sirius Therapeutics Inc.
- Sirnaomics Inc.
- Suzhou Sanegene Bio Inc.
- Synerk Inc.
- Thermo Fisher Scientific Inc.
- Vir Biotechnology, Inc.
- Wave Life Sciences USA, Inc.
Table of Contents
1. Preface1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. siRNA Therapeutics Market, by Drug Agent
8.1. Introduction
8.2. Givosiran
8.3. Inclisiran
8.4. Lumasiran
8.5. Nedosiran
8.6. Patisiran
8.7. Vutrisiran
9. siRNA Therapeutics Market, by Delivery Systems
9.1. Introduction
9.2. Lipid Nanoparticles
9.3. Peptide Delivery Systems
9.4. Polymer Conjugates
10. siRNA Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Intravenous (IV)
10.3. Subcutaneous
11. siRNA Therapeutics Market, by Therapeutic Categories
11.1. Introduction
11.2. Cardiovascular Disorders
11.3. Immunological Disorders
11.4. Infectious Diseases
11.4.1. Bacterial Infections
11.4.2. Viral Infections
11.5. Metabolic Disorders
11.6. Neurological Disorders
11.6.1. Alzheimer's Disease
11.6.2. Parkinson's Disease
11.7. Oncology
11.7.1. Hematologic Malignancies
11.7.1.1. Leukemia
11.7.1.2. Lymphoma
11.7.2. Solid Tumors
11.7.2.1. Breast Cancer
11.7.2.2. Lung Cancer
11.7.2.3. Prostate Cancer
12. siRNA Therapeutics Market, by End-User
12.1. Introduction
12.2. Contract Research Organizations
12.3. Hospitals & Clinics
12.4. Pharmaceutical Companies
12.5. Research & Academic Institutes
13. Americas siRNA Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa siRNA Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific siRNA Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Alnylam Pharmaceuticals Inc.
16.3.2. Alys Pharmaceuticals Inc.
16.3.3. Arbutus Biopharma Corporation
16.3.4. Arcturus Therapeutics, Inc. by Alcobra Ltd.
16.3.5. Aro Biotherapeutics Co.
16.3.6. Arrowhead Pharmaceuticals Inc.
16.3.7. Atalanta Therapeutics
16.3.8. Biocon Ltd.
16.3.9. e-Therapeutics Plc
16.3.10. Eli Lilly and Company
16.3.11. Ionis Pharmaceuticals Inc.
16.3.12. Merck & Co. Inc.
16.3.13. Moderna Therapeutics
16.3.14. Novartis AG
16.3.15. Novo Nordisk A/S
16.3.16. Phio Pharmaceuticals, Inc.
16.3.17. Quark Pharmaceuticals inc.
16.3.18. Risen Pharma Tech Co Ltd
16.3.19. Roche Holding AG
16.3.20. Shanghai Argo Biopharmaceutical Co., Ltd.
16.3.21. Silence Therapeutics plc
16.3.22. Sirius Therapeutics Inc.
16.3.23. Sirnaomics Inc.
16.3.24. Suzhou Sanegene Bio Inc.
16.3.25. Synerk Inc.
16.3.26. Thermo Fisher Scientific Inc.
16.3.27. Vir Biotechnology, Inc.
16.3.28. Wave Life Sciences USA, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SIRNA THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. SIRNA THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. SIRNA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SIRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SIRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SIRNA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY GIVOSIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY INCLISIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LUMASIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY NEDOSIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY VUTRISIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PEPTIDE DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY POLYMER CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 71. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 72. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 74. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 75. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 76. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 77. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 78. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 79. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 81. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 84. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 85. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 87. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 88. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 132. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 133. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 135. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 136. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 137. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 138. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 139. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 140. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 142. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 145. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 146. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 147. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 148. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 149. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 162. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 163. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 165. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 166. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 167. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 168. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 169. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 170. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 172. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 173. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 175. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 176. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 177. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 178. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 179. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 180. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 212. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 213. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 215. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 216. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 217. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 218. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 219. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 220. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 232. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 233. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 235. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 236. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 237. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 238. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 239. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 240. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 242. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 245. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 246. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 247. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 248. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 249. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 250. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 272. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 273. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 275. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 276. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 277. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 278. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 279. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 280. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 281. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 282. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 283. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 285. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 286. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 287. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 288. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 289. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 290. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 301. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 302. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 303. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 304. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 305. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 306. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 307. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 308. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 309. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 310. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 311. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 312. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 313. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 315. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 316. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 317. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 318. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 319. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 320. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 326. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 327. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 328. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 329. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 330. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 334. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY THERA
Samples
LOADING...
Companies Mentioned
The companies profiled in this siRNA Therapeutics market report include:- Alnylam Pharmaceuticals Inc.
- Alys Pharmaceuticals Inc.
- Arbutus Biopharma Corporation
- Arcturus Therapeutics, Inc. by Alcobra Ltd.
- Aro Biotherapeutics Co.
- Arrowhead Pharmaceuticals Inc.
- Atalanta Therapeutics
- Biocon Ltd.
- e-Therapeutics Plc
- Eli Lilly and Company
- Ionis Pharmaceuticals Inc.
- Merck & Co. Inc.
- Moderna Therapeutics
- Novartis AG
- Novo Nordisk A/S
- Phio Pharmaceuticals, Inc.
- Quark Pharmaceuticals inc.
- Risen Pharma Tech Co Ltd
- Roche Holding AG
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Silence Therapeutics plc
- Sirius Therapeutics Inc.
- Sirnaomics Inc.
- Suzhou Sanegene Bio Inc.
- Synerk Inc.
- Thermo Fisher Scientific Inc.
- Vir Biotechnology, Inc.
- Wave Life Sciences USA, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 187 |
| Published | May 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 3.25 Billion |
| Forecasted Market Value ( USD | $ 5.33 Billion |
| Compound Annual Growth Rate | 10.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
